NA
SCPH

Nordwand Advisors’s scPharmaceuticals SCPH Stock Holding History

Nordwand Advisors’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-500
Closed -$2.51K – 173
2024
Q1 		$2.51K Buy
+500
New +$2.8K ﹤0.01% 148

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Nordwand Advisors's SCPH Position: Q2 2024 in Review

Nordwand Advisors sold out of scPharmaceuticals (SCPH) in Q2 2024, closing a stake of 500 shares — an estimated $2.51K sold.

Nordwand Advisors first reported a position in SCPH in Q1 2024 and held it in 1 quarter. The position peaked at $2.51K in Q1 2024. 77 funds tracked by Wall St. Rank hold SCPH as of Q2 2024.

  • Nordwand Advisors reported no remaining scPharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Nordwand Advisors sold 500 scPharmaceuticals shares in Q2 2024, an estimated $2.51K.
  • Nordwand Advisors first reported a position in scPharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Nordwand Advisors's scPharmaceuticals position peaked at $2.51K in Q1 2024.
  • 77 funds tracked by Wall St. Rank held scPharmaceuticals as of Q2 2024.

Based on Nordwand Advisors's 13F filing for Q2 2024, filed 5 Aug 2024.